XOMA Royalty Corp

XOMA Royalty Corp (XOMAP) is a US-listed equity tracked across major market indices. XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.

The company reports trailing twelve-month revenue of $12.32M and net income of $4.46M. Key metrics include a return on equity of 4.8%, a debt-to-equity ratio of 1.71.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for XOMAP to support both active traders and long-term investors.